26 de noviembre de 2020

Scientists develop almost 180 COVID-19 vaccine candidates worldwide

The continuous race for a COVID-19 vaccine triggered the development of around 180 vaccine candidates worldwide, of which 35 are currently in human trials.
Such data were highlighted in a press briefing by the Director General of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus who warned about the need to accelerate equitable access to vaccines, diagnosis and therapy against COVID-19.

‘In February, the WHO brought together hundreds of scientists and researchers to identify research priorities (…). Some therapies, such as the use of dexamethasone, demonstrated their efficacy in seriously ill and critical COVID-19 patients; and now there are around 180 ongoing vaccines, including 35 in clinical trials,’ he noted.

In this regard, the spokesperson for the international body in Russia, Melita Vujnovic, told the Sputnik news agency, that the WHO welcomes as hopeful the fact that over 30 candidate vaccines are going through different phases of clinical trials.

She further stressed that the organization continues to cooperate with Russian scientists and authorities and is eagerly awaiting the possibility of studying the details of the Sputnik V vaccine tests.

Recently, a study issued in The Lancet certified that Sputnik V is safe and produces an immune response.

Other valuable candidates are China’s Sinovac, which began phase III several weeks ago after the company was authorized in Brazil to carry out experimental tests on volunteers.

In Latin America, the Cuban vaccine candidate Soberana 01 started clinical trials on August 24 and after injecting 40 volunteers between 18 and 80 years old, health authorities do not report adverse reactions.

(Taken from Prensa Latina)

Redacción RCM

Equipo de editores del sitio web de Radio Ciudad del Mar.

Ver todas las entradas de Redacción RCM →

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *